Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2004

View Archived Issues

ORG-50081 enters phase II/III studies as nonhormonal menopausal therapy

Treatment commences in Dutch study of IMC-11F8 in solid tumors

Active Biotech's TTS-CD3 receives fast track designation for NSCLC

Approvable letter for hyponatremia drug YM-087

Fuji and JCR to enter into licensing agreement for JR-013

Diovan approved in Sweden to treat high-risk heart attack patients

Hexvix found fileable in 26 European countries

Priority review for Velcade for second-line multiple myeloma

APD-125 enters phase I study for insomnia

Controlled-release topiramate development stopped in obesity, type 2 diabetes

Iroxanadine shows promise for cardiovascular disease in mouse study

Prometheus Laboratories to market Entocort EC

Remicade sBLA for psoriatic arthritis accepted for filing

MVA-HPV-IL2 studied in new phase II trial for precancerous cervical lesions

FDA Advisory Committee positively endorses clofarabine for ALL

Intrinsa: potential risks outweigh sexual benefits

Soybean isoflavone metabolite inhibits bone loss in vivo

Conivaptan increases serum sodium levels in patients with hyponatremia

Tumor necrosis factor inhibitor may attenuate postmyocardial infarction ventricular remodeling

Hydrocortisone NO-releasing derivative shows greater antiinflammatory effects than parent compound

Orion claims new treatments for epilepsy using alpha2-adrenoceptor antagonists

New antimitotic agents described in patent literature

Taisho and Arena Pharmaceuticals jointly patent MCH receptor antagonists

Researchers at Meiji Seika isolate new compounds from Penicillium sp.

Janssen team presents new PCL-beta2 inhibitors

New factor Xa inhibitors in early development at Merck

PIN1 inhibitors described by Pfizer scientists

Syrrx researchers report DPP4 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...